Author

S-H.I. Ou

Observed names: S. Ou, S.I. Ou

Institutions: University of California, Irvine, University of California, Irvine Medical Center, UC Irvine Chao Family Comprehensive Cancer Center

Observed institutions: University of California, Irvine, University of California, Irvine Medical Center, UC Irvine Chao Family Comprehensive Cancer Center

OpenAlex ID: A5113917536

LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study

2024 · B. Besse, S-H. Lee, et al. · Annals of Oncology · 50

P50.04 Amivantamab in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

2021 · M. Nagasaka, K. Goto, et al. · Journal of Thoracic Oncology · 8

540P Entrectinib in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) or NTRK fusion-positive solid tumours: Analysis of response by line of therapy

2020 · S.V. Liu, F. De Braud, et al. · Annals of Oncology · 1

P2.14-24 An Open-Label Randomized Phase II Study of Combining Osimertinib With and Without Ramucirumab in TKI-Naïve EGFR-Mutant Metastatic NSCLC

2019 · X. Le, V. Zhu, et al. · Journal of Thoracic Oncology

P11 Afatinib in Patients with EGFR Mutation-Positive (EGFRm+) NSCLC Harboring Uncommon Mutations: Overview of Clinical Data

2018 · O. Arrieta, P. De Marchi, et al. · Journal of Thoracic Oncology

Works count: 5

Citation count: 59

H-index: 2

I10-index: 1